ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SYNC Syncona Limited

123.00
0.20 (0.16%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.16% 123.00 122.20 122.80 124.00 122.20 122.60 632,316 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.55 814.75M
Syncona Limited is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 122.80p. Over the last year, Syncona shares have traded in a share price range of 105.00p to 162.20p.

Syncona currently has 666,733,588 shares in issue. The market capitalisation of Syncona is £814.75 million. Syncona has a price to earnings ratio (PE ratio) of -14.55.

Syncona Share Discussion Threads

Showing 18301 to 18325 of 18925 messages
Chat Pages: Latest  733  732  731  730  729  728  727  726  725  724  723  722  Older
DateSubjectAuthorDiscuss
13/6/2018
07:01
Autolus to ipo on Nasdaq 22/6
ltinvestor
10/6/2018
11:59
Autolus has a unique advantage over other car T therapies in that their car T has a built in “off switch”.This will help reduce adverse reactions found with other T cell therapies.Autolus excites me more than their other subsidiary holdings and in time has the potential to be worth billions...
ltinvestor
08/6/2018
11:25
Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share.

The registration statement discloses an indicative pricing range for the proposed offering of U.S.$15.00 – U.S.$17.00 per ADS. This would represent an increase in value of Syncona’s current shareholding in Autolus (compared to the 30 April 2018 sterling holding value) of £49.5 – £67.7 million[1] (7.4p-10.2p per Syncona share). The proposed maximum aggregate offering amount specified in the filing is U.S.$125.0 million, which assumes that the offering price is at the midpoint of the indicative pricing range and does not include the underwriters’ option to purchase additional ADSs.

alan@bj
31/5/2018
16:47
Indeed it is moving along nicely. I like the business models which allows exposure to a portfolio of life science start-ups which would otherwise be unavailable for investment. Definitely less risky than buying in to early stage companies reliant on a single technology.
audigger
25/5/2018
14:54
.....and today another high.Where is everybody?
ltinvestor
24/5/2018
08:22
Today the share price has reached an all time high and no wonder with its holdings.Under the radar at the moment with Pi’s but not institutions.
ltinvestor
15/5/2018
13:20
hxxps://www.businesswire.com/news/home/20180514005319/en/Blue-Earth-Diagnostics-Announces-Presentation-Fluciclovine-18F

Apparently a poster on the results of the LOCATE clinical trial (NCT02680041) will be presented in the next week. 220 patients for:

Primary Outcome Measures :
The fraction of patients for whom 18F-fluciclovine PET/CT alters patient planned treatment through detection of disease. [ Time Frame: 2-22 days post PET CT ]
The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT


Secondary Outcome Measures :
The fraction of patients for whom 18F-fluciclovine PET/CT alters patient actual treatment [ Time Frame: 6 months ]

The rate of detection of any disease site by 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ]
The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT

The rate of detection of 1) local and pelvic disease and 2) distant metastases with 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ]

The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally

luxaeterna1
15/5/2018
10:56
I was very fortunate and bought in during the first few weeks of the fund @ about £1.30. Thankfully it was a modest purchase, offsetting some fairly terrible other stocks in my portfolio!
luxaeterna1
13/5/2018
09:48
I bought a large number at £1.65 so very happy.
ltinvestor
13/5/2018
08:42
I am invested here. I bought in at 159p.
alan@bj
13/5/2018
07:14
Alan.Autolus have built a “switch” in the Car T cell so they have the ability to can turn off the treatment at any time.Syncona is under the PI radar at the moment but not the institutions.This is one investment that you lock in the bottom drawer and watch it grow year on year.Dyor and do not take this as investment advice...
ltinvestor
12/5/2018
13:37
Thank you Iti.
alan@bj
12/5/2018
12:19
It is on one of the forms and apparently is an approximation.If you google Autolus you will find a couple of articles re the listing etc
ltinvestor
11/5/2018
16:24
Where did you find that information, Iti? Is Syncona participating in the fund raising?
alan@bj
11/5/2018
15:42
Raising $100m prior to listing..
ltinvestor
10/5/2018
19:26
Therein lies opportunity :-)
DL

davidlloyd
08/5/2018
07:20
No price movement on announcement as no details.
brexitplus
08/5/2018
06:42
Syncona have a 38.6% share of Autolus and the Nasdaq listing should show a significant uplift in Synconas nav.
ltinvestor
08/5/2018
06:12
Autolus files for proposed initial public offering in the United States

8 May 2018

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share. All ADSs to be sold in the proposed IPO will be offered by Autolus. Autolus intends to apply to list its ADSs on the Nasdaq Global Market under the ticker symbol “AUTL”. The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.

brexitplus
02/5/2018
18:11
The highly encouraging rns in full:
rambutan2
02/5/2018
08:35
Axumin sales price is ~ $3000 per dose, at the RNS announced of 5000 doses per quarter that should result in approximate ~ $60m annual sales revenue, already indicated as profitable.

Now - with sales rising at roughly 35% per quarter there is serious room for expansion! At current growth trend Blue Earth could be a $200m revenue co in 12 months time?

luxaeterna1
02/5/2018
07:20
Yes, the portfolio companies are progressing very well.Autolus possible Ipo in the US?
ltinvestor
02/5/2018
07:18
Excellent news from Blue Earth.
alan@bj
10/4/2018
07:39
Novartis acquiring Avexis for $8.7bn!Syncona own 74% Of Freeline Which is in the same field....
ltinvestor
28/3/2018
15:17
Not sure why the fall, you'd have to assume some stock hit the market somewhere.

I had not realised the scope for further Fluciclovine PET imaging, they currently have a EU/US license for prostate scanning, with further clinical trials ongoing with female breast cancer ( hxxps://clinicaltrials.gov/ct2/show/NCT03036943 ), cervical, ovarian, endometrial and Brain-glioma cancers.

There was an unusual medical science case documented in January 2018, a 77year old prostate cancer patient was diagnosed with a secondary breast cancer tumour that was discovered by the fluciclovine Quite interesting considering it has not been validated for that condition (in practice many tumours could be be flagged in a similar way).

luxaeterna1
Chat Pages: Latest  733  732  731  730  729  728  727  726  725  724  723  722  Older

Your Recent History

Delayed Upgrade Clock